Funding
Department of Surgical Gastroenterology and Transplantation, Rigshospitalet
Danish Cancer Society
The Kornerup Fund
The Aage and Johanne Louis-Hansen Fund
The Aase and Ejnar Danielsen Fund
The Walter and O. Kristiane Christensen Fund
The Kathrine and Vigo Skovgaard Fund
Den Midtjyske Bladfond
The Agnes and Poul Friis Fund
The Glunz and Jensen Fund
The Sophus and Astrid Jacobsen Fund
The Arvid Nilsson Fund
The Danish Bank Fund
The Johannes Fog Fund
The Eva and Henry Fraenkel Fund
The Hartmann Bros. Fund
The KID Fund
The Henrik Henriksen Fund
The King Christian X's Fund
The Oda and Hans Svenningsen Fund
The Else and Mogens Wedell-Wedellsborg Fund
The Einar Willumsen Fund
The Willy and Ingeborg Reinhard Fund
The Friedrich and Else Boehm Fund
The Toyota Fund Denmark
The IMK Fund
The Danish Medical Research Fund
The Beckett Fund
Hvidovre University Hospital
ARTICLE ABSTRACT
Purpose: To investigate the prognostic and predictive biomarker value of type IV collagen in colorectal cancer.Experimental Design: Retrospective evaluation of two independent cohorts of patients with colorectal cancer included prospectively in 2004–2005 (training set) and 2006–2008 (validation set). Plasma samples were available from 297 (training set) and 482 (validation set) patients. Type IV collagen determinations were performed using an ELISA. From the training set, 222 tumors were available for IHC. Clinical and follow-up data were retrieved from patient files and national registries.Results: High levels of type IV collagen showed independent prognostic significance in both cohorts with hazard ratios (HRs; for a one-unit change on the log base 2 scale) of 2.25 [95% confidence intervals (CIs), 1.78–2.84; P < 0.0001] and 2.24 (95% CI, 1.75–2.86; P < 0.0001) for the training and validation set, respectively. The prognostic impact was present both in patients with metastatic and nonmetastatic disease. The predictive value of the marker was investigated in stage II and III patients. In the training set, type IV collagen was prognostic both in the subsets of patients receiving and not receiving adjuvant antineoplastic therapy. However, in the validation set, the prognostic effect of the marker vanished when looking at patients who received adjuvant antineoplatic therapy (HR 0.90; 95% CI, 0.42–1.93) but was still present in the group not receiving adjuvant chemotherapy (HR 2.88; 95% CI, 1.98–4.21).Conclusions: The results indicate clinical validity of type IV collagen as a prognostic biomarker in colorectal cancer, although the suggested predictive role of the marker should be validated. Clin Cancer Res; 22(10); 2427–34. ©2015 AACR.
